Invitae announces new partnership with Alnylam Pharmaceuticals to provide TTR gene testing for patients suspected of having hereditary ATTR amyloidosis
Invitae Corporation (NVTA)
Last invitae corporation earnings: 2/19 04:05 pm
Check Earnings Report
US:NYSE Investor Relations:
ir.invitae.com/investor-relations/default.aspx
Company Research
Source: PR Newswire
SAN FRANCISCO, April 3, 2017 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, has announced a program in partnership with Alnylam Pharmaceuticals, the leading RNAi therapeutics company, to provide genetic testing for hereditary ATTR (hATTR) amyloidosis, a rare, progressive and life-threatening disease caused by a mutation in the TTR gene which causes accumulation of misfolded proteins in nerves and cells of other organs. The Alnylam Act™ program is aimed at encouraging early genetic testing to aid in the prompt genetic diagnosis of patients with hATTR amyloidosis. Genetic testing determines whether a patient is a carrier of a mutation in the TTR gene, thereby confirming an hATTR amyloidosis diagnosis and guiding clinical decision-making."Genetic testing is essential for the diagnosis of hATTR to differentiate the disease from other forms of amyloidosis. Accurate diagnosis guides clinical decisions for t
Show less
Read more
Impact Snapshot
Event Time:
NVTA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVTA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVTA alerts
High impacting Invitae Corporation news events
Weekly update
A roundup of the hottest topics
NVTA
News
- Invitae gets court approval for five-month bankruptcy sale [Reuters]Reuters
- Invitae gets court approval for five-month bankruptcy sale [Yahoo! Finance]Yahoo! Finance
- Genetic Testing Firm Invitae, Backed by SoftBank and Cathie Wood, Files for Chapter 11 [Yahoo! Finance]Yahoo! Finance
- Invitae files for Chapter 11 bankruptcy to address huge debt load [Seeking Alpha]Seeking Alpha
- Genetic test maker Invitae files for bankruptcy protection in US [Reuters]Reuters
NVTA
Earnings
- 11/8/23 - Miss
NVTA
Sec Filings
- 2/14/24 - Form 8-K
- 2/13/24 - Form SC
- 2/13/24 - Form SC
- NVTA's page on the SEC website